1. Surveillances V. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) China, 2020. China CDC Weekly. 2020; 2(8): 113-22. doi:10.46234/ccdcw2020.032

2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama 2020. doi:10.1001/jama.2020.1585, PMid:32031570 PMCid:PMC7042881

3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506. doi:10.1016/S0140-6736(20)30183-5 PMid:31986264

4. Sawalha AH, Zhao M, Coit P, Lu Q. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol 2020; 215: 108410. doi:10.1016/j.clim.2020.108410 PMid:32276140 PMCid:PMC7139239

5. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. NEJM 2020; 382(17): e38. doi:10.1056/NEJMc2007575 PMid:32268022 PMCid:PMC7161262

6. Longo DL. Harrison's principles of internal medicine. 20th ed. New York: McGraw-Hill; 2018.

7. Gupta L, Misra DP, Agarwal V, Balan S, Agarwal V. Response to: 'Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort' by Costa et al. Ann Rheum Dis 2020. doi:10.1136/annrheumdis-2020-217953 PMid:32527864

8. Tariq S, Van Eeden C, Tervaert JW, Osman MS. COVID-19, rheumatic diseases and immune dysregulation-a perspective. Clin Rheumatol 2021; 40: 433-42. doi:10.1007/s10067-020-05529-y, PMid:33411143 PMCid:PMC7788381

9. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmunity Rev 2020; 19(5): 102523. doi:10.1016/j.autrev.2020.102523 PMid:32205186 PMCid:PMC7102591

10. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223):507-13. doi:10.1016/S0140-6736(20)30211-7 PMid:32007143

11. D'Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19( and rheumatic disease: a comparative cohort study from a US 'hot spot'. Ann Rheum Dis 2020; 79: 1156-62. doi:10.1136/annrheumdis-2020-217888 PMid:32457048 PMCid:PMC7456555

12. Malek Mahdavi A, Varshochi M, Hajialilo M, Dastgiri S, Khabbazi R, Khabbazi A, et al. Factors associated with COVID-19 and its outcome in patients with rheumatoid arthritis. Clin Rheumatol (2021). doi:10.1007/s10067-021-05830-4 PMid:34189674 PMCid:PMC8241410

13. D'Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, et al. COVID-19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study. Arthritis Rheumatol 2021; 73(6): 914-20. doi:10.1002/art.41619 PMid:33305544 PMCid:PMC8169514

14. Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rúa-Figueroa Í, Gonzalez-Gay MA, et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis 2020; 79(7): 988-90. doi:10.1136/annrheumdis-2020-217948 PMid:32503857 PMCid:PMC7307213

15. Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, et al. Covid-19 in immune-mediated inflammatory diseases-case series from New York. NEJM 2020. doi:10.1056/NEJMc2009567, PMid:32348641 PMCid:PMC7204427

16. Coskun Benlidayi I, Kurtaran B, Tirasci E, Guzel R. Coronavirus disease 2019 (COVID-19( in a patient with ankylosing spondylitis treated with secukinumab: a case-based review. Rheumatol Int 2020:1-10. doi:10.1007/s00296-020-04635-z PMid:32591970 PMCid:PMC7319213

17. Mason A, Rose E, Edwards CJ. Clinical management of Lupus patients during the COVID-19 pandemic. Lupus 2020; 29(13): 1661-72. doi:10.1177/0961203320961848 PMid:33059530

18. Gazzaruso C, Carlo Stella N, Mariani G, Tamburlini A, Garini P, Freddi E, et al. Impact of anti-rheumatic drugs and steroids on clinical course and prognosis of COVID-19. Clin. Rheumatol. 2020; 39(8): 2475-7. doi:10.1007/s10067-020-05239-5, PMid:32548723 PMCid:PMC7297548

19. Moiseev S, Avdeev S, Brovko M, Yavorovskiy A, Novikov PI, Umbetova K, et al. Rheumatic diseases in intensive care unit patients with COVID-19. Ann Rheum Dis 2021; 80(2): e16. doi:10.1136/annrheumdis-2020-217676 PMid:32434823

20. Elemam NM, Maghazachi AA, Hannawi S. COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies. Curr Med Res Opin 2021; 37(6): 929-38. doi:10.1080/03007995.2021.1906637 PMid:33754931 PMCid:PMC8040489

21. Robinson PC, Liew DFL, Liew JW, Monaco C, Richards D, Shivakumar S, et al. The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. Med (N Y) 2020; 1(1): 90-102. doi:10.1016/j.medj.2020.11.005 PMid:33294881 PMCid:PMC7713589

22. Lamontagne SJ, Pizzagalli DA, Olmstead MC. Does inflammation link stress to poor COVID-19 outcome? Stress Health 2021; 37(3): 401-14. doi:10.1002/smi.3017 PMid:33315291

23. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci 2020; 57(6): 389-99. doi:10.1080/10408363.2020.1770685, PMid:32503382 PMCid:PMC7284147

24. Https://www.uptodate.com/contents/table-of-contents/calculators/rheumatology-calculators

25. Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021; 80(7): 930-42. doi:10.1136/annrheumdis-2020-219498 PMid:33504483 PMCid:PMC7843211

26. Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open 2021; 7(1): e001464. doi:10.1136/rmdopen-2020-001464 PMid:33479021 PMCid:PMC7823432

27. Santos CS, Morales CM, Álvarez ED, Castro CÁ, Robles AL, Sandoval TP. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. Clin Rheumatol 2020; 39(9): 2789-96. doi:10.1007/s10067-020-05301-2 PMid:32720259 PMCid:PMC7383119

28. Scirè CA, Carrara G, Zanetti A, Landolfi G, Chighizola C, Alunno A, et al. COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19). Clin Exp Rheumatol 2020; 38(4): 748-53.

29. Espinosa G, Prieto-González S, Llevadot M, Marco-Hernández J, Martínez-Artuña A, Pérez-Isidro A, et al. The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia. Clin. Rheumatol 2021; 40: 2057-63. doi:10.1007/s10067-021-05675-x PMid:33677725 PMCid:PMC7936868

30. Vaid N, Ardissino M, Reed TAN, Goodall J, Utting P, Miscampbell M, et al. Clinical characteristics and outcomes of immunosuppressed patients hospitalized with COVID-19: experience from London. J Intern Med 2021; 289: 385-94. doi:10.1111/joim.13172 PMid:32902028

31. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis2020; 79(5):667-8. doi:10.1136/annrheumdis-2020-217424 PMid:32241793 PMCid:PMC7211079

32. Goyal M, Patil P, Pathak H, Santhanam S, Goel A, Sharma V, et al. Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India. Ann Rheum Dis 2021; 80:71. doi:10.1136/annrheumdis-2020-218013 PMid:32669305

33. Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis 2021;1-10.doi:10.1136/annrheumdis-2021-eular.1632 PMid:34049860 PMCid:PMC8172266

34. Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis 2020; 79: 837-9. doi:10.1136/annrheumdis-2020-217566 PMid:32332072

35. Khoubnasabjafari M, Jouyban A, Malek Mahdavi A, Namvar L, Esalatmanesh K, Hajialilo M, et al. Prevalence of COVID-19 in patients with rheumatoid arthritis (RA) already treated with hydroxychloroquine (HCQ) compared with HCQ-naive patients with RA: a multicentre cross-sectional study. Postgrad Med J 2021; 1-5 doi:10.1136/postgradmedj-2020-139561 PMid:35232849

36. Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. J Gastroenterol 2020; 159(2): 481-91.e3. doi:10.1053/j.gastro.2020.05.032 PMid:32425234 PMCid:PMC7233252

37. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395(10223): 473-5. doi:10.1016/S0140-6736(20)30317-2 PMid:32043983

38. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis 2020. doi:10.1093/cid/ciaa478 PMid:32338708 PMCid:PMC7197612

39. Wilson K, Chotirmall S, Bai C, Rello J. COVID-19: interim guidance on management pending empirical evidence. Last Updated April 2020; 3.

40. Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists' perspective on coronavirus disease 19 (COVID-19( and potential therapeutic targets. Clin Rheumatol 2020; 39(7): 2055-62. doi:10.1007/s10067-020-05073-9 PMid:32277367 PMCid:PMC7145936

41. Pablo's JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis 2020; 79(12): 1544-9. doi:10.1136/annrheumdis-2020-218296 PMid:32796045

42. Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis 2020; 99: 47-56. doi:10.1016/j.ijid.2020.07.029 PMid:32721533 PMCid:PMC7381888

43. Henry BM, Cheruiyot I, Vikse J, Mutua V, Kipkorir V, Benoit J, et al. Lymphopenia and neutrophilia at admission predicts severity and mortality in patients with COVID-19: a meta-analysis. Acta Biomed 2020; 91(3(: e2020008.

44. Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J 2021; 42: 2270-9. doi:10.1093/eurheartj/ehaa1103 PMid:33448289 PMCid:PMC7928982

45. Pradhan A, Olsson PE. Sex differences in severity and mortality from COVID-19: are males more vulnerable?. Biol Sex Differ 2020; 53: 1-11. doi:10.1186/s13293-020-00330-7 PMid:32948238 PMCid:PMC7498997

46. Bloom CI, Drake TM, Docherty AB, Lipworth BJ, Johnston SL, Nguyen-Van-Tam JS, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med 2021; 9: 699-711. doi:10.1016/S2213-2600(21)00013-8 PMid:33676593

47. Li L, Yang L, Gui S, Pan F, Ye T, Liang B, et al. Association of clinical and radiographic findings with theoutcomes of 93 patients with COVID-19 in Wuhan,China. Theranostics 2020; 10(14): 6113-21. doi:10.7150/thno.46569 PMid:32483442 PMCid:PMC7255034

48. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. AJR 2020; 214: 1072-7. doi:10.2214/AJR.20.22976 PMid:32125873

49. Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020; 69(7): 1213-7. doi:10.1136/gutjnl-2020-321411 PMid:32354990

50. Liu Y, Mao B, Liang S, Yang JW, Lu HW, Chai YH, et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur Respir J 2020; 55: 2001112. doi:10.1183/13993003.01112-2020 PMid:32312864 PMCid:PMC7173682